BF
RVMD icon

BOK Financial’s Revolution Medicines RVMD Stock Holding History

BOK Financial’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10
Closed -$354 – 1302
2025
Q1 		$354 Hold
10
– – ﹤0.01% 1243
2024
Q4 		$418 Buy
+10
New +$505 ﹤0.01% 1253

Other funds holding RVMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BOK Financial's RVMD Position: Q2 2025 in Review

BOK Financial sold out of Revolution Medicines (RVMD) in Q2 2025, closing a stake of 10 shares — an estimated $354 sold.

BOK Financial first reported a position in RVMD in Q4 2024 and held it in 2 quarters. The position peaked at $418 in Q4 2024. 307 funds tracked by Wall St. Rank hold RVMD as of Q2 2025.

  • BOK Financial reported no remaining Revolution Medicines position as of Q2 2025 after selling out during the quarter.
  • BOK Financial sold 10 Revolution Medicines shares in Q2 2025, an estimated $354.
  • BOK Financial first reported a position in Revolution Medicines in Q4 2024 and held it in 2 quarters.
  • BOK Financial's Revolution Medicines position peaked at $418 in Q4 2024.
  • 307 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2025.

Based on BOK Financial's 13F filing for Q2 2025, filed 12 Aug 2025.